Progression-free survival: Gaining on overall survival as a gold standard and acceleratingdrug development

Cancer Journal

Volumn 15, Issue 5, 2009, Pages 386-394

  Lebwohl, David ^a   Kay, Andrea ^a   Berg, William ^a   Baladi, Jean Francois ^a   Zheng, Ji ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Efficacy; Measurement; Overall survival; Progression free survival; Surrogate

Indexed keywords

ALTRETAMINE; AMIFOSTINE; ANASTROZOLE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BEXAROTENE; BLEOMYCIN; BUSULFAN; CAPECITABINE; CARBOPLATIN; CARMUSTINE; CISPLATIN; CLADRIBINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EXEMESTANE; FLUDARABINE; FLUOROURACIL; FOLINIC ACID; FULVESTRANT; GEMCITABINE; IMATINIB; IRINOTECAN; OXALIPLATIN; PLACEBO; RAZOXANE; SUNITINIB; UNINDEXED DRUG;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SURVIVAL; CARDIOTOXICITY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL RESEARCH; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; DRUG APPROVAL; DRUG MARKETING; DRUG RESEARCH; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; GOLD STANDARD; HAIRY CELL LEUKEMIA; HEAD AND NECK CANCER; HUMAN; KIDNEY CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; NEPHROTOXICITY; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMYELOCYTIC LEUKEMIA; RANDOMIZED CONTROLLED TRIAL; REVIEW; SKIN DEFECT; XEROSTOMIA;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG APPROVAL; HUMANS; NEOPLASMS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 70350141192     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3181b9c5ec     Document Type: Review

References (37)

1. Pazdur R. Endpoints for assessing drug activity in clinical trials. Oncologist. 2008;13(suppl 2):19-21.
2. Beckman M. More clinical cancer treatments judged by progression-free rather than overall survival. J Natl Cancer Inst. 2007;99:1068-1069.
3. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics. Biotechnol Law Rep. 2007;26:375-386.
4. European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on the evaluation of anticancer medicinal products in man. December 2005. Document CPMP/EWP/205/95/Rev.3/Corr. Available at: http://www.tga.gov.au/docs/pdf/euguide/ewp/020509enrev3.pdf. Accessed September 22, 2009.
5. Bast RC, Thigpen JT, Arbuck SG, et al. Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR public workshop. Gynecol Oncol. 2007;107:173-176.
6. Chia SK, Speers CH, D'yachkova Y, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer. 2007;110:973-979.
7. Grothey A, Sargent D, Goldberg RM, et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracilleucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004;22:1209-1214.
8. Sargent DJ, Hayes DF. Assessing the measure of a new drug: is survival the only thing that matters? J Clin Oncol. 2008;26:1922-1923.
9. Demetri GD, Huan X, Garrett CR, et al. Novel statistical analysis of long-term survival to account for crossover in a phase III trial of sunitinib (SU) vs. placebo (PL) in advanced GIST after imatinib (IM) failure [abstract]. J Clin Oncol. 2008;26(15S):10524.
10. Johnson JR, Williams G, Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol. 2003;21: 1404-1411.
11. Pignatti F. EMEA Experience with Endpoints for Oncology Drug Approval. EMEA/CHMP Biomarkers Workshop. December 16, 2005. Available at: http:// www.emea.europa.eu/pdfs/human/biomarkers/04PIGNATTI.pdf. Accessed June 3, 2009.
12. Panageas KS, Ben-Porat L, Dickler NM, et al. When you look matters: the effect of assessment schedule on progression-free survival. J Natl Cancer Inst. 2007;99:428-432.
13. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-216.
14. WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland: World Health Organization Offset Publication No. 48;1979.
15. Thiesse P, Ollivier L, Di Stefano-Louineau D, et al. Response rate accuracy in oncology trials: reasons for interobserver variability. J Clin Oncol. 1997; 15:3507-3514.
16. Ford R, Schwartz L, Dancey J, et al. Lessons learned from independent central review. Eur J Cancer. 2009;45:268-274.
17. Dodd LE, Korn EL, Friedlin B, et al. Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense? J Clin Oncol. 2008;26:3791-3796.
18. Sargent D. General and statistical hierarchy of appropriate biologic endpoints. Oncology (Williston Park). 2006;20:5-9.
19. US Food and Drug Administration, American Society of Clinical Oncology, American Association of Cancer Research. Meeting Summary. Ovarian Cancer Endpoints Workshop. 2006. Available at: http://www.fda.gov/CDER/ drug/cancer-endpoints/ovarian-summary.pdf Accessed April 23, 2009.
20. Tang PA, Bentzen SM, Chen EX, et al. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol. 2007;25:4562-4568.
21. Buyse M, Burzykowski T, Carroll K, et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol. 2007;25: 5218-5224.
22. Yothers G. Toward progression-free survival as a primary end point in advanced colorectal cancer. J Clin Oncol. 2007;25:5153-5154.
23. Miksad RA, Zietemann V, Gothe R, et al. Progression-free survival as a surrogate end point in advanced breast cancer. Int J Technol Assess Health Care. 2008;24:371-383.
24. Burzykowski T, Buyse M, Piccart-Gebhart MJ, et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol. 2008;26:1987-1992.
25. AVASTIN® (Bevacizumab) Prescribing Information. South San Francisco, CA: Genentech, Inc.; 2008.
26. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic factors of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17: 2530-2540.
27. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-134.
28. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Eng J Med. 2007;356:115-124.
29. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomized, double-blind phase III trial. Lancet. 2007;370:2103-2111.
30. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon-alfa, or both for advanced renal-cell carcinoma. N Eng J Med. 2007;356:2271-2281.
31. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449-456.
32. Kay A, Motzer R, Escudier B, et al. Updated data from a phase III randomized trial of everolimus (RAD001) versus PBO in metastatic renal cell carcinoma (mRCC). ASCO 2009 Genitourinary Cancers Symposium. Abstract 278.
33. Kane RC, Farrell AT, Saber H, et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res. 2006;12:7271-7278.
34. Figlin RA, Hutson TE, Tomczak P, et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2008;26(May 20 suppl): Abstract 5024 and Oral Presentation. Available at: http://www.asco.org/ASCOv2/MultiMedia/Virtual- Meeting?& vmview-vm-session-presentations-view&confID-55&sessionID- 363. Accessed June 3, 2009.
35. Knox JJ. Progression-free survival as endpoint in metastatic RCC? Lancet. 2008;372:427-429.
36. Delea TE, Khuu A, Kay A, et al. Association between treatment effects on disease progression (DP) endpoints and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2009;27(15s):Abstract 5105.
37. Sargent DJ, Wieand HS, Haller DG, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,989 patients on 18 randomized trials. J Clin Oncol. 2005;23:8664-8670.